OncoMatch/Clinical Trials/NCT03596086
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
Is NCT03596086 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies ADV/HSV-tk (gene therapy) for glioblastoma multiforme.
Treatment: ADV/HSV-tk (gene therapy) — Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — for glioblastoma
has had prior surgery and radiotherapy /chemotherapy for the glioblastoma
Must have received: radiation therapy — for glioblastoma
has had prior surgery and radiotherapy /chemotherapy for the glioblastoma
Must have received: chemotherapy — for glioblastoma
has had prior surgery and radiotherapy /chemotherapy for the glioblastoma
Cannot have received: immunomodulatory therapy
Exception: allowed if >3 months prior
Prior treatment with immunomodulatory therapy, immunotherapy, and/or gene vector therapy in the past 3 months
Cannot have received: immunotherapy
Exception: allowed if >3 months prior
Prior treatment with immunomodulatory therapy, immunotherapy, and/or gene vector therapy in the past 3 months
Cannot have received: gene vector therapy
Exception: allowed if >3 months prior
Prior treatment with immunomodulatory therapy, immunotherapy, and/or gene vector therapy in the past 3 months
Cannot have received: cytotoxic chemotherapy
Exception: allowed if >3 weeks prior
Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug for this brain tumor within 3 weeks of study treatment start
Cannot have received: radiation therapy
Exception: allowed if >3 weeks prior
Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug for this brain tumor within 3 weeks of study treatment start
Cannot have received: immunotherapy
Exception: allowed if >3 weeks prior
Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug for this brain tumor within 3 weeks of study treatment start
Cannot have received: investigational drug
Exception: allowed if >3 weeks prior
Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug for this brain tumor within 3 weeks of study treatment start
Lab requirements
Blood counts
Platelet count > 100,000/ml, ANC > 1500/ml, Hgb > 10 gm/dL, Normal partial thromboplastin time (PTT) and Pro-Thrombin Time (PT)
Kidney function
serum creatinine < 1.5 mg/dL
Liver function
T. bilirubin < 2.5 mg/dL, ALT, AST, GGT and AP < 2 x normal
serum creatinine < 1.5 mg/dL; T. bilirubin < 2.5 mg/dL, ALT, AST, GGT and AP < 2 x normal; Platelet count > 100,000/ml , ANC> 1500/ml , Hgb> 10 gm/dL; Normal partial thromboplastin time (PTT) and Pro-Thrombin Time (PT)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Houston Methodist Neurological Institute · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03596086 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunomodulatory therapy, immunotherapy, gene vector therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages